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The mature heart valves are dynamic structures composed of highly organized cell lineages and extracellular matrices. The discrete architecture
of connective tissue within valve leaflets and supporting structures allows the valve to withstand life-long functional demands and changes in
hemodynamic forces and load. The dysregulation of ECM organization is a common feature of heart valve disease and can often be linked to
genetic defects in matrix protein structure or developmental regulation. Recent studies have identified specific regulatory pathways that are active
in the developing valve structures and also control cartilage, tendon, and bone development. This review will focus on the regulatory hierarchies
that control normal and abnormal heart valve development in parallel with other connective tissue cell types.
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Developmental defects of heart valves represent 20–30% of
all cardiovascular malformations, and heart valve disease is a
leading cause of morbidity and mortality in adults (Hoffman and
Kaplan, 2002; Supino et al., 2004). The etiology of heart valve
disease is relatively undefined, but there is recent evidence to
suggest that valve disease discovered later in life may be related
to developmental defects in valvulogenesis (Cripe et al., 2004;
Garg et al., 2005). During embryonic development, the heart
valves arise from endocardial cushions that elongate and
remodel into the valve leaflets and their supporting apparatus
(Armstrong and Bischoff, 2004; Schroeder et al., 2003). Recent
work has contributed to a basic understanding of the cellular
and molecular regulation of endocardial cushion formation, but
less is known about how the highly organized extracellular☆ Grant Sponsors: P50-HL074728 SCCOR in Pediatric Heart Development
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doi:10.1016/j.ydbio.2006.03.027matrix (ECM) in the mature valves develops (Armstrong and
Bischoff, 2004; Person et al., 2005; Schroeder et al., 2003).
There is increasing evidence that valve leaflets and
supporting structures are composed of diversified ECM
compartments with characteristics of different types of
connective tissues (Rabkin-Aikawa et al., 2005). Recent work
has demonstrated that regulatory hierarchies active in develop-
ing cartilage, tendon, and bone also are important in heart valve
maturation and ECM remodeling (Garg et al., 2005; Lange and
Yutzey, 2006; Lincoln et al., 2006). In diseased heart valves,
there is a distinct loss of ECM organization associated with
changes in mechanical properties that ultimately leads to
dysfunction (Rabkin et al., 2001; Schoen, 2005). However,
the molecular events that result in aberrant ECM expression and
distribution characteristic of valve disease are largely unknown.
In many tissues, including heart muscle and bone, the regulatory
pathways required for normal development also contribute to
pathogenesis later in life (Chien and Karsenty, 2005). The
structural properties and regulatory hierarchies common to the
heart valves and other connective tissues will be the focus of
this review in the context of normal development and disease
mechanisms.
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In a given individual, the heart beats approximately 100,000
times a day, and the heart valves must coordinately open and
close with each beat to achieve unidirectional blood flow.
Normally, the semilunar (SL) valves of the outflow tract (OFT)
and mitral and tricuspid valves of the atrioventricular (AV) canal
function without obstruction or regurgitation during the cardiac
cycle to direct blood flow through the cardiac chambers and
great vessels. Normal SL valves are composed of three cusps,
whereas the AV valves consist of two or three leaflets supported
by chordae tendineae that insert into the ventricular papillary
muscles. Although the gross anatomy of the SL and AV valves
is distinct, the mechanical requirements for elasticity, com-
pressibility, stiffness and strength, as well as durability
throughout the lifespan of an individual, are similar for both
sets of valves (Rabkin-Aikawa et al., 2005; Schoen, 2005;
Vesely, 2005). This is achieved in large part from highly
organized and compartmentalized ECM composition of the
valves and their supporting structures.
Electron microscopy and immunohistochemical studies of
human valve tissue identified three distinct layers of ECM
within the valve leaflets: the fibrosa, spongiosa and atrialis
(AV)/ventricularis (SL) (Fig. 1) (Garcia-Martinez et al., 1991;
Gross and Kugel, 1931; Rabkin-Aikawa et al., 2005). The
orientation of these matrix layers is the same relative to blood
flow for the SL and AV valves, with the fibrosa layer situated
away from blood flow, the atrialis or ventricularis adjacent to
blood flow and the spongiosa layer in between. Each of the
matrix layers provides specific mechanical properties to the
valve leaflet due to the composition and organization of ECM
proteins present in each compartment. The fibrosa layer
provides strength, whereas the atrialis/ventricularis layers areFig. 1. Schematic representation of extracellular matrix compartmentalization of
themature atrioventricular (AV) and semilunar (SL) heart valves. ECMofAV (A)
and SL (B) valves is organized in stratified layers relative to blood flow (red
arrows). The atrialis (A) in the AV valve or the ventricularis (V) in the SL is
composed of elastin fibers (gray lines). Proteoglycans (blue) are predominant in
the spongiosa (S) layer, while collagen fibers arranged in parallel networks
(yellow) are present in the fibrosa (F) layer. The supporting chordae tendineae
(CT) (black arrows) of the AV valve are composed of collagen and elastic fibers.
In panel B, muscle is indicated in red and collagen-rich fibrous annulus is yellow.more elastic. The spongiosa layer in between allows movement
between the surface cell layers and acts as a shock absorber
during valve closure. Together, these matrix layers and their
associated interstitial cells provide the cellular and molecular
components for development and maintenance of normal valve
structure and function throughout life.
The connective tissue matrix within the fibrosa layer is
predominantly composed of parallel, dense collagen fibers that
confer stiffness and strength to the valve leaflets (Icardo and
Colvee, 1995; Rabkin-Aikawa et al., 2005). During develop-
ment, collagen types I, II, III, V, VI and XI are expressed in the
immature remodeling valves, although extensive collagen fiber
networks are not yet apparent (Klewer et al., 1998; Lincoln et
al., 2004; Lincoln and Hinton, unpublished). During postnatal
development in mice, the type I collagen fiber network becomes
more extensive and is predominant in the fibrosa layer of the
valves (Hinton, unpublished). The structural assembly of these
fibers provides resilience and rigidity to the valve leaflet in
order to close the valve orifices effectively without prolapse into
the adjacent chamber (Gross and Kugel, 1931; Rabkin-Aikawa
et al., 2005). The structural and mechanical properties provided
by specific collagen fibers are also apparent in other connective
tissue systems. Fiber alignment of collagen types I, III and V is
apparent in remodeling tendons and bones (Birk, 1997; Zhang
et al., 2005). In tendon, the assembly of collagen matrix is
required for flexibility with varying degrees of stiffness, while
in the bone, type I collagen provides a substratum for
mineralization (Silver et al., 2002). In addition to collagen
fibers, the fibrosa layer also expresses tenascin, a glycoprotein
used as a ‘classic’ marker of tendon development (Hurle et al.,
1989; Kardon, 1998; Lincoln et al., 2004, 2006). Thus, the
fibrosa matrix layer of the heart valves shares cellular and
mechanical properties with tendon and bone ECM that confer
both stiffness and strength.
The spongiosa matrix layer of the mature valve is rich in
proteoglycans, with a lower abundance of collagens than the
fibrosa layer, thereby providing a more compressible matrix and
allowing for changes in leaflet shape during the cardiac cycle
(Rabkin-Aikawa et al., 2005). In the mouse and chicken, there
are several proteoglycans and collagens expressed in the
spongiosa layer during remodeling, including aggrecan,
versican, perlecan, cartilage-link protein, and type II and XI
collagen, but there are differences in expression patterns
between species (Costell et al., 2002; Henderson and Cobb,
1998; Hurle et al., 1994; Lincoln et al., 2004, 2006; Lincoln,
unpublished; Mjaatvedt et al., 1998). Although not exclusive to
the heart valves, these proteoglycans and collagens are
characteristic of cartilage and provide properties to resist
compression and maintain structural integrity (Poole et al.,
2001). Therefore, shared molecular and structural properties of
cell matrix of the spongiosa layer and cartilage cell types are
reflected in the protein composition of these tissues.
The atrialis/ventricularis matrix layer is predominantly
composed of aligned fibers of elastin interspersed with short
collagen fibers in a radial arrangement (Schoen, 1997; Scott
and Vesely, 1995). This type of elastic cell matrix also is
characteristic of vascular smooth muscle and could be related to
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this has not yet been demonstrated (Laurent et al., 2005). The
elasticity of the ECM on the surface of the valves is important
for the leaflet's ability to stretch and retract during the cardiac
cycle (Rabkin-Aikawa et al., 2005; Vesely, 1998). Elastic fibers
are also present in the chordae tendineae that support the AV
valve leaflets through insertion into the papillary muscles of the
ventricles (Liao and Vesely, 2004). Tissue flexibility and
extensibility provided by elastic fibers are apparent in several
tissue types including arterial walls, skin, tendons, and
ligaments, as well in the valves and their supporting structures
(Kielty et al., 2002).
Heart valve disease and connective tissue disorders
Histological changes in valve ultrastructure and histopath-
ologic alterations in ECM organization are characteristic of
many forms of valve disease and dysfunction (Table 1) (Akhtar
et al., 1999; Nasuti et al., 2004; Ng et al., 2004; Rabkin et al.,
2001; Tamura et al., 1995; Walker et al., 2004). Valve
dysfunction can be characterized as stenosis, defined as failure
of the valve leaflet to fully open often due to mechanical
stiffness, or as insufficiency, caused by inefficient closing of the
valve associated with myxomatous or thickened valve tissue
(Rabkin-Aikawa et al., 2005). In the United States, 95,000
diseased valves required replacement in 2003, and valve
calcification was frequently observed (Thom et al., 2006).
These disease lesions occur with the deposition of mineralized
calcium leading to progressive valve stiffening, incomplete
valve opening, and subsequent valve stenosis (Mohler et al.,
2001; Rajamannan et al., 2003). Congenital heart valve disease
often includes histological changes in proteoglycan, collagen,
and elastic fibers resulting in myxomatous or “floppy” valves,
associated with mitral valve prolapse (MVP) (Ng et al., 2004;
Rabkin et al., 2001). These thickened valves loose their rigidity
and resilience due to loss of ECM stratification and are the most
common cause of valve insufficiency (Akhtar et al., 1999;
Nasuti et al., 2004; Tamura et al., 1995). Disorganization of
ECM layers also occurs with aortic valve stenosis resulting from
bicuspid aortic valve (BAV), which is the most common
congenital valve anomaly and is also associated with valve
calcification later in life (Cripe et al., 2004; Garg et al., 2005;
Hinton and Benson, unpublished). This finding suggests that
congenital and adult valve disease may actually be a continuum
of dysfunction resulting from developmental anomalies that
lead to progressively abnormal distribution and organization of
ECM proteins over time.
In the human population, heart valve dysfunction is a
frequent manifestation of connective tissue disorders that affect
cartilage, tendon, bone, and skin (Table 1). Marfan syndrome,
caused by mutations in Fibrillin-1, is characterized by skeletal
malformations and cardiovascular anomalies, including BAV
and heart valve insufficiency (Dietz et al., 2005; Lee et al.,
1991; Weyman and Scherrer-Crosbie, 2004). Ehlers–Danlos
syndrome associated with mutations in several collagen or
tenascin genes, and Stickler syndrome, caused by mutations in
type II or XI collagen, both include premature connective tissuefragility in skin and joints (Burch et al., 1997; Liberfarb and
Goldblatt, 1986; Schalkwijk et al., 2001). Heart valve
dysfunction, including MVP, also has been reported in these
patient populations (Liberfarb and Goldblatt, 1986). Histolog-
ical analyses of these affected valves have not been reported, but
it is predicted that mutations in ECM protein genes would affect
the organization of stratified valve layers resulting in valve
insufficiency. Nonsyndromic mutations in several ECM protein
genes also have been reported for a variety of limb and skin
malformations (Table 1). Since the ECM and cell lineages that
make up these affected tissues are similar to those in developing
heart valves, these individuals also may provide insights into
previously unappreciated forms of valve disease. In addition, a
more complete understanding of the developmental regulation
of these specific connective tissue cell types will likely be
informative of valve disease mechanisms.
Valvulogenesis
The process by which valve precursors remodel into mature
valves is an active area of recent research using animal model
systems. In chicken embryos, ECM stratification within the
valve leaflets is well defined in the AVand SL valves (Lincoln et
al., 2004, 2006; Hinton, unpublished). Therefore, avian
embryos provide an excellent system for examination of
regulatory hierarchies and remodeling events in isolated
precursor populations under controlled experimental conditions
(Lincoln et al., 2006). In the mouse, the valve leaflets are
comparatively thinner than in the chick and ECM stratification
is less well-defined (Hinton, unpublished). Nevertheless,
transgenic and gene targeting approaches in mice have
advanced our understanding of cellular and molecular mechan-
isms required for valve remodeling and maturation in vivo
(Armstrong and Bischoff, 2004; Person et al., 2005; Yutzey et
al., 2005). Additional genes required for early stages of
valvulogenesis have been identified in zebrafish, however, the
basic ECM organization in the mature fish valve has yet to be
determined (Beis et al., 2005; Walsh and Stainier, 2001).
Collectively, these systems have been used to define regulatory
processes that control the initial formation and maturation of the
heart valves during development.
Valvulogenesis begins with the formation of endocardial
cushions in the AV canal and OFT during looping stages of the
heart tube that correspond to Hamburger–Hamilton stage 14 in
chicken embryos and E9.5 in mice (Person et al., 2005).
Cushion formation is initiated with expansion of the cardiac
jelly and epithelial–mesenchymal transformation (EMT) of
endocardial cells (Eisenberg and Markwald, 1995, 1977; Person
et al., 2005). The resulting endocardial cushions contain an
undifferentiated mesenchymal cell population of valve progen-
itor cells surrounded by ECM composed predominantly of the
proteoglycan glycosaminoglycan hyaluronan (HA) (Lincoln et
al., 2004; Schroeder et al., 2003). The molecular and cellular
regulation of EMT has been extensively studied and thoroughly
reviewed in recent publications (Armstrong and Bischoff, 2004;
Person et al., 2005; Schroeder et al., 2003). The regulatory
events that occur after cushion formation to produce highly
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increasingly active area of research.
Heart valve differentiation is characterized by the expression
of specific signaling molecules, transcription factors, ECM
proteins, and associated regulatory enzymes in the developing
leaflets and supporting structures. Recent work has demon-
strated that the precursors for these diversified structures are
present in a common population of progenitor cells within the
endocardial cushions (de Lange et al., 2004; Lincoln et al.,
2004, 2006). AV valve cell lineage diversification begins when
the cushions fuse to separate the right and left channels of the
AV canal and form the valve primordia (Lincoln et al., 2006).
Following fusion, the valve primordia begin to express
transcription factors and structural proteins associated with
differentiation of the valve leaflets and supporting structures
(Hurle et al., 1994; Lincoln et al., 2004, 2006; Montero et al.,
2002). Strikingly, many of these regulatory genes and structural
proteins also are expressed in developing cartilage, tendon, and
bone cell lineages (Brent and Tabin, 2002; Karsenty and
Wagner, 2002).
Heart valve differentiation also is associated with a decrease
in precursor cell proliferation in the valve primordia. The
mesenchymal cells of the endocardial cushions exhibit a
uniformly high proliferation index (de Lange et al., 2004;
Lincoln et al., 2004). After fusion, differential rates of
proliferation are observed in the valve primordia with the
highest levels present at the distal tips, consistent with a distal
outgrowth mechanism for valve elongation. Signaling through
the Ras-MAPK pathway is a critical component of valve
progenitor cell cycle regulation as indicated by the presence of
activated dpERK throughout the endocardial cushion mesen-
chyme and localized at the distal tips of the more mature valve
primordia (Gitler et al., 2003b; Liberatore and Yutzey, 2004;
Yutzey et al., 2005). Likewise, aberrant function of the SHP-2
phosphatase modulates Ras activation through ERK1/2 and
alters valve progenitor proliferation in genetically modified
mice or cultured chicken embryo valve progenitors (Araki et
al., 2004; Krenz et al., 2005). Mutations in the human gene
encoding SHP-2, PTPN11, have been implicated in congenital
heart defects, including valve malformations, associated with
Noonan syndrome (Tartaglia et al., 2001). Remodeling of the
valve primordia is accompanied by dramatic reduction in
proliferation, and mutant mice with increased or decreased
cellularity of the endocardial cushions exhibit premature
lethality (Armstrong and Bischoff, 2004; Lincoln et al.,
2004; Yutzey et al., 2005). Therefore, cell cycle regulation is
crucial for establishing a pool of progenitor cells in the
endocardial cushions that then withdraws from the cell cycle
and differentiates to form the diversified structures of the valve
leaflets and supporting apparatus.
Heart valve remodeling includes both the deposition and
proteolysis of ECM proteins and results in a stereotypic
stratified ECM that is the structural basis for valve function
throughout life (Rabkin-Aikawa et al., 2005; Schoen, 2005).
Valve maturation is characterized by increasing complexity of
ECM protein expression in different compartments of the valves
that develop into leaflet fibrosa, spongiosa, and atrialis/ventricularis layers and supporting structures. Mutagenesis
studies in mice have demonstrated the requirements for a variety
of ECM proteins in heart valve formation and function (Table
1). Loss of the proteoglycans perlecan or versican results in
midgestational lethality from endocardial cushion maturation
defects (Costell et al., 2002; Mjaatvedt et al., 1998). Additional
mutations in collagen or fibrillin genes are less severe and lead
to valve malformations detected postnatally (Ng et al., 2004;
Lincoln, unpublished). Matrix remodeling enzymes, such as
matrix metalloproteinases (MMPs), and their inhibitors, tissue
inhibitors of metalloproteinases (TIMPS), also are expressed in
the remodeling valves (Barth et al., 2005; Dreger et al., 2002;
Rabkin et al., 2001). The functions of MMPs and TIMPs in the
developing valves have not been fully characterized, but
increased expression of several of these proteins is observed
with ECM disorganization associated with human myxomatous
valve disease (Fondard et al., 2005; Rabkin et al., 2001; Soini
et al., 2001). The balance of ECM protein expression and
remodeling underlies heart valve structure and function during
development and likely is important for valve homeostasis
throughout life. However, the regulatory hierarchies that
control the development of valve cell lineages with character-
istics of distinct connective tissues are just beginning to be
uncovered. Much more extensive information is available
regarding the development of related connective tissue cell
types in other organ systems, and there is increasing evidence
for conserved regulatory pathways in the heart valves with
those of developing cartilage, tendon, and bone (Fig. 2).
Remodeling heart valves share regulatory pathways with
developing cartilage, tendon, and bone
Recent studies have demonstrated that regulatory interactions
between specific signaling molecules, transcription factors, and
structural genes or remodeling enzymes occur in related
connective tissue cell types with diverse developmental origins.
The relationships between these regulatory hierarchies are
complex and involve multiple feedback mechanisms, but
defined pathways involved in specific aspects of valve formation
are beginning to emerge. Three of these regulatory pathways are
reviewed below.
BMP2–Sox9–aggrecan
In the developing limb buds, the transcription factor Sox9 is
required for differentiation of chondrogenic cell lineages, and
mice with conditional inactivation of Sox9 display an array of
skeletal malformations (Akiyama et al., 2002; Bi et al., 1999;
Chimal-Monroy et al., 2003; Kist et al., 2002). In the heart,
Sox9 has been implicated in endocardial cushion formation, and
predominant expression in the remodeling valve leaflets is
suggestive of a role in later stages of valve remodeling
(Akiyama et al., 2004; Lincoln et al., 2004, 2006; Lincoln,
unpublished; Montero et al., 2002). Sox9 target genes in
cartilage cell lineages encode type II and XI collagen, aggrecan
and cartilage-link protein, and several of these ECM proteins
also are expressed in the mature valves (Bell et al., 1997;
Bridgewater et al., 1998; Chimal-Monroy et al., 2003; Kou and
Table 1
Extracellular matrix proteins and molecular regulatory pathways involved in connective tissue and heart valve development and disease
Role in connective tissue development Role in cardiac development Associated human disease
A. Extracellular matrix proteins
Elastin Expressed in periphery of tendons
and fibrils anchoring tendons to
skeletal elements (Ros et al., 1995)
Required for arterial development; expressed
atrialis/ventricularis of mature AV and SL
valves (Li et al., 1998; Rabkin et al., 2001;
Hinton, unpublished)
Williams syndrome supravalvular aortic
stenosis (Ewart et al., 1993a,b; Morris et al.,
1993); cutis laxa (Zhang et al., 1999)
Fibrillin-1 Connective tissue microfibril;
key component of elastic fibers
(Kielty et al., 1998)
Marfan syndrome models display mitral
valve prolapse (Brown et al., 1975;
Glesby and Pyeritz, 1989; Ng et al., 2004)
Marfan syndrome (Dietz et al., 2005;
Lee et al., 1991); Weill–Marchesani
syndrome (Faivre et al., 2003); MASS
syndrome (Glesby and Pyeritz, 1989)
Perlecan 60% mutant mice die at birth with
skeletal and chondrodysplasia
(Arikawa-Hirasawa et al., 1999)
Expressed in AV and outflow tract (OFT)
endocardial cushions; mutant mice have
OFT anomalies (Costell et al., 2002;
Handler et al., 1997)
Schwartz–Jampel syndrome (Nicole et al.,
2000)
Tenascin Expressed in tendon progenitor and
mature tendon cells (Chiquet and
Fambrough, 1984)
Expressed in supporting apparatus of AV
and SL valve structures (Lincoln et al.,
2004, 2006)
Ehlers–Danlos syndrome type 3
(Burch et al., 1997)
Type I collagen Mutant mice die at E12.5 with
vascular defects
(Lohler et al., 1984)
Expressed in AV and OFT endocardial
cushions and mature valves
(Lincoln et al., 2004)
Ehlers–Danlos syndrome classic type;
osteogenesis imperfecta (Nuytinck et al.,
2000; Sykes et al., 1985)
Type II collagen Required for chondrogenesis
(Vandenberg et al., 1991)
Expressed in developing chick and
mouse heart valves (Lincoln et al.,




(Ahmad et al., 1991; Lee et al., 1989;
Snead et al., 1994; Tsipouras et al., 1983;
Vissing et al., 1989)
Type III collagen Required for type I collagen
fibrillogenesis (Liu et al., 1997)
Mutant mice die in adulthood due to
blood vessel rupture; expressed in fibrosa
layer of mature AV and SL valves
(Hinton, unpublished)
(Liu et al., 1997)
Ehlers–Danlos syndrome Type III, IV
(Superti-Furga et al., 1988)
Type XI collagen Required for formation of cartilage
collagen fibrils (Li et al., 1995)
Expressed in remodeling valve structures;
mitral valve prolapse in Stickler syndrome
(Ahmad et al., 2003; Liberfarb and
Goldblatt, 1986) (Lincoln et al.,
unpublished) (Yoshioka et al., 1995)
Stickler syndrome
Marshall syndrome (Griffith et al., 1998;
Snead et al., 1996)
Versican Required for precartilaginous
aggregation and cartilage
differentiation
(Williams et al., 2005)
Mutant mice die at E10.5 with hypoplastic
endocardial cushions and right cardiac
chamber malformations (Mjaatvedt et al.,
1998)
B. Regulatory pathways in connective tissue development
BMP Promotes chondrogenesis;
regulates sox9 expression
(Yoon and Lyons, 2004)
Required for EMT; regulates sox9 and
aggrecan expression (Lincoln et al.,
2006; Ma et al., 2005; Sugi et al., 2004)
Sox9 Required for cartilage formation
through BMP2 signaling
(Bi et al., 1999; Yoon and
Lyons, 2004)
Required for EMT; regulated by BMP2 in
chick EC cells (Akiyama et al., 2004;
Lincoln et al., 2006)
Campomelic dysplasia (Bi et al., 2001;
Foster et al., 1994)
Aggrecan Mutant mice die at birth with
skeletal malformations
(Watanabe et al., 1997)
Expressed in chicken valve leaflet
(Lincoln et al., 2006)
Spondyloepiphyseal
dysplasia (Gleghorn et al., 2005)
Cartilage-link protein Mutant mice die at birth with
cartilage defects
(Watanabe and Yamada, 1999)
Expressed in AV and OFT endocardial
cushions and mature valves
(Lincoln, unpublished)
FGF4 Regulates tendon formation in
somitic compartment
(Brent and Tabin, 2004)
Involved in EC proliferation and
expressed in EC and AV myocardium
(Sugi et al., 2003)
Scleraxis Expressed in tendon progenitors;
regulates tenascin
(Edom-Vovard et al., 2002)
Expressed in supporting apparatus of
AV and OFT valve
(Lincoln et al., 2004, 2006)
RANKL Required for osteoclast
development
(Mizuno et al., 1998)
Expressed in endocardial cells of
remodeling valves (Lange and Yutzey,
2006)
Osteopetrosis (Kong et al., 1999)
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Table 1 (continued )
Role in connective tissue development Role in cardiac development Associated human disease
B. Regulatory pathways in connective tissue development
NFATc1 Required for osteoclast
differentiation
(Hirotani et al., 2004)
Required for heart valve formation
(de la Pompa et al., 1998; Ranger et al., 1998)
(continued on next page)
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1997; Yoshioka et al., 1995). The direct regulation of these
genes by Sox9 in the valve primordia has not yet been
demonstrated, but the expression of these matrix proteins in
regions where Sox9 is present is consistent with a role for Sox9
in the development of proteoglycan-rich compartments of the
developing valves.
Upstream regulators of sox9 gene expression were first
identified in limb bud chondrogenic precursors, and the main
inducing factor of sox9 expression in these cells is BMP2
(Chimal-Monroy et al., 2003). BMP2 is also expressed in the
AV myocardium adjacent to the developing valves that express
sox9 and has been implicated in cushion formation as well as
later events in valve remodeling (Delot, 2003; Lincoln et al.,
2006; Ma et al., 2005). In the limb cartilage, one of the best-
characterized downstream target genes of Sox9 is the
chondroitin sulfate proteoglycan aggrecan (Chimal-Monroy
et al., 2003). Strikingly, BMP2 induction of sox9 and aggrecan
expression also occurs in chick valve precursor cells treated in
culture (Lincoln et al., 2006). In avian embryos, aggrecan-
expressing valve cells with characteristics of cartilage cell
types occupy the spongiosa layer of the remodeled valve,
consistent with the compressible property of the proteoglycan
matrix (Lincoln et al., 2006). The observation that BMP2
activates sox9 and aggrecan in both cartilage and valveFig. 2. Regulatory pathways required for chondrogenesis, tendon formation, and
osteoclast differentiation are active in remodeling AV heart valves. Simplified
regulatory hierarchies involved in aspects of heart valve compartmentalization
and remodeling are represented. BMP signaling, Sox9, and aggrecan are present
in developing valve leaflets and cartilage cell lineages. Tenascin and scleraxis
expression is affected by FGF signaling in valve supporting structures and
tendon precursors. RANKL expression, NFATc1 activation, and cathepsin K are
apparent in endothelial cells of at the distal tips of the remodeling valves and also
in differentiating osteoclasts involved in bone matrix remodeling.precursor cells represents surprising cellular and molecular
similarities between the two systems.
FGF–scleraxis–tenascin
In the developing tendons, FGF4 activates the MAPK
(ERK1/2) signaling cascade to promote expression of the bHLH
transcription factor scleraxis (Edom-Vovard et al., 2002; Smith
et al., 2005). Scleraxis subsequently induces expression of
tenascin, a glycoprotein prominent in tendon cell types (Edom-
Vovard et al., 2002; Hurle et al., 1989; Kardon, 1998; Ros et al.,
1995; Schweitzer et al., 2001). All of the components of this
regulatory pathway are present in remodeling valves (Karabagli
et al., 2002; Liberatore and Yutzey, 2004; Sugi et al., 2003). In
particular, scleraxis and tenascin are distinctly expressed in the
supporting structures of the valve leaflet and chordae tendineae
(Lincoln et al., 2004, 2006). Mice null for scleraxis die from
mesoderm defects during gastrulation; therefore, further
targeted genetic studies are necessary to determine a require-
ment for scleraxis during cell lineage differentiation of valve
precursor cells (Brown et al., 1999). However, insights have
been gained from in vitro studies in which FGF4, through
ERK1/2 signaling, is able to induce expression of scleraxis and
tenascin in valve progenitor cells from chicken embryos
(Lincoln et al., 2006). This conservation in the regulation of
scleraxis and tenascin expression represents further shared
regulatory pathways in heart valve precursors and other
connective tissue cell types, including tendon.
In the limb buds, diversification of cartilage and tendon cell
lineages from a common precursor population is regulated by
antagonism between BMP and FGF signaling pathways (Brent
and Tabin, 2002; Tickle, 2002). In these cells, BMP2 not only
promotes chondrogenesis, but also inhibits tendon develop-
ment, while FGF4 promotes tendon differentiation at the
expense of chondrogenesis (Edom-Vovard and Duprez, 2004;
Edom-Vovard et al., 2002). Likewise, inhibitors of BMP
signaling promote tendon differentiation, and FGF inhibition
increases chondrogenesis. A similar antagonistic relationship
between these signaling pathways in the differentiation of cell
lineages characterized by aggrecan or tenascin expression also
was observed in heart valve progenitor cells (Lincoln et al.,
2006). In addition, the BMP inhibitor Noggin represses sox9
and aggrecan while inducing expression of scleraxis and
tenascin in both systems (Capdevila and Johnson, 1998;
Lincoln et al., 2006; Schweitzer et al., 2001). The antagonism
between these BMP and FGF pathways extends to the level of
the signaling intermediates, Smad1/5 and ERK1/2, since
corresponding changes in phosphorylation of these proteins
were observed with the different signaling conditions in valve
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have defined an antagonistic relationship between BMP and
FGF signaling pathways that controls cartilage versus tendon
cell determination in limb bud progenitors and also functions in
diversification of heart valve precursor cells.
RANKL–NFATc1–cathepsin K
Expression of the transcription factor NFATc1 is required
for heart valve remodeling in mice; however, the initial reports
did not provide information regarding the molecular mecha-
nism by which this occurs (de la Pompa et al., 1998; Ranger
et al., 1998). NFATc1 also is required for osteoclast lineage
development, and it has been useful to apply knowledge of
NFAT function obtained in this cell type to the analysis of
heart valve regulatory mechanisms (Boyle et al., 2003; Lange
and Yutzey, 2006). Osteoclasts are specialized cells derived
from the macrophage lineage that resorb and remodel the bone
matrix during development and homeostasis. In osteoclasts,
receptor activator of NFκB ligand (RANKL), a member of
the TNF ligand family, signals through its receptor RANK to
promote differentiation of bone-resorbing osteoclasts (Boyle
et al., 2003). NFATc1 is a necessary transcriptional effector
of RANKL signaling in osteoclasts through direct regulation
of enzymes involved in bone matrix degradation and remo-
deling, such as tartrate-resistant acid phosphatase (TRAP/
Acp5) and the cysteine protease cathepsin K (Ctsk) (Ikeda et
al., 2004; Matsumoto et al., 2004; Takayanagi et al., 2002).
Thus, in osteoclasts, NFATc1 is responsible for the tran-
scriptional activation of specific extracellular matrix degrad-
ing enzymes, and the heart phenotype in nfatc1−/− mouse
embryos is consistent with a similar regulatory function in valve
remodeling.
During cardiac development, RANKL, its receptor RANK,
and the downstream matrix protease Ctsk are co-expressed with
NFATc1 in the endocardium of the remodeling heart valves
(Lange and Yutzey, 2006). This pathway appears to be active
during valve development since RANKL treatment of cultured
hearts stimulates cardiac expression of NFATc1 and Ctsk, and
Ctsk expression is lost in remodeling valves of nfatc1−/−
embryos (Lange and Yutzey, 2006). Together, these findings
provide initial evidence for RANKL-mediated NFATc1 func-
tion in the regulation of genes directly involved in heart valve
matrix remodeling. While RANKL signaling and Ctsk are
known to be essential for osteoclast development, abnormalities
in heart valve formation have not been reported with mutation
of these genes in mice or humans (Gelb et al., 1996; Gowen et
al., 1999; Li et al., 2000). Therefore, additional regulatory
signals may contribute to NFATc1 activation and ECM
remodeling during valve leaflet formation, or there may be
valve defects associated with these gene mutations that have not
been fully appreciated. Further studies are necessary to
determine the exact role of RANKL signaling and Ctsk in
heart valve remodeling as well as to identify additional
pathways that affect NFATc1 activation. Of interest, the balance
of RANKL and its receptor antagonist osteoprotegerin (OPG)
controls the extent of bone mineralization and contributes to
vascular calcification (Bucay et al., 1998; Theoleyre et al.,2004). Therefore, signaling through the RANK receptor and
control of NFATc1 activation may have important regulatory
roles, not only in heart valve development, but also in adult
valve homeostasis and disease mechanisms associated with
aging.
Conclusions and perspectives
Recent research has revealed striking similarities in the
cellular and molecular mechanisms that control heart valve cell
differentiation with those of developing cartilage, tendon, and
bone. It is likely that these findings do not represent the full
regulatory conservation of these tissue types, and that additional
pathways originally characterized in developing cartilage,
tendon, and bone will be found to be important for heart
valve lineage differentiation and remodeling. For example,
there is initial evidence that Notch and canonical Wnt signaling
pathways are active during valve remodeling, but the specific
cells and processes affected by these pathways are not well-
characterized (Garg et al., 2005; Gitler et al., 2003a). Insights
into the functions of these pathways in the valves could be
provided by extensive mechanistic studies of cartilage, tendon,
and bone development, already in the literature. The conserva-
tion in genetic mechanisms between these systems has certainly
advanced our understanding of heart valve remodeling thus far
and will likely provide exciting avenues of research for the
future.
There is an increasing understanding of the specific
connective tissue cell types that form the diverse structures of
the heart valves and emerging evidence for dysregulation of
these cell types associated with valve disease. Transcriptional
regulators, such as Sox9, scleraxis, and NFATc1, are expressed
during valve lineage differentiation and patterning, but further
studies are necessary to determine the precise functions of these
genes during valvulogenesis in vivo. It is tempting to speculate
that these critical regulators of valve development also have a
role in aberrant ECM expression and organization associated
with valve disease, but induction of these factors during valve
pathogenesis has not yet been demonstrated. In addition,
appropriate viable animal models for molecular and cellular
studies of myxomatous or calcified valves are not widely
available. Human genetic studies are beginning to provide
evidence that developmental pathways important in valvulo-
genesis also contribute to adult valve disease (Cripe et al., 2004;
Garg et al., 2005). However, more research is necessary to
determine if valve disorders characterized by abnormal or
mineralized ECM include reactivation of developmental gene
programs or if these molecular mechanisms can be exploited for
new clinical therapies.
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